Bramante Carolyn T, Raatz Sarah, Bomberg Eric M, Oberle Megan M, Ryder Justin R
Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, MN, United States.
Division of General Internal Medicine, University of Minnesota Medical School, Minneapolis, MN, United States.
Front Endocrinol (Lausanne). 2020 Jan 15;10:883. doi: 10.3389/fendo.2019.00883. eCollection 2019.
Obesity is a complex disease influenced by many neurohormonal pathways which regulate body weight toward homeostasis. Presently, the disease of obesity effects over a billion individuals worldwide with scalable treatment options in dire need. Pharmacologic interventions for obesity have been developed to help promote weight loss in individuals with obesity. This area is rapidly developing and will only exponentially increase to serve the demand for persons with obesity seeking biologically orientated solutions to treat their disease. Therefore, understanding the cardiovascular risks and benefits of these weight loss medications is of particularly importance due to obesities strong association with cardiovascular (CV) disease risk. Moreover, past experiences with pharmacotherapy agents with weight loss properties have demonstrated an association with adverse CV outcomes, leading to market removal, in most cases and concerns over using similar medications. To better understand the CV risks and benefits pharmacotherapy agents used for weight loss, this review will discuss medications which are FDA-approved for weight loss, as well as medications commonly used off-label for this indication. The goal is to provide an overview of the risks and benefits many of these medications can offer to help guide clinical decision making and patient education.
肥胖是一种复杂的疾病，受许多神经激素途径影响，这些途径将体重调节至稳态。目前，肥胖症影响着全球超过10亿人，急需可扩展的治疗选择。已开发出用于肥胖症的药物干预措施，以帮助肥胖个体减轻体重。这一领域正在迅速发展，并且只会呈指数级增长，以满足寻求以生物学为导向的解决方案来治疗其疾病的肥胖者的需求。因此，鉴于肥胖与心血管（CV）疾病风险密切相关，了解这些减肥药物的心血管风险和益处尤为重要。此外，过去具有减肥特性的药物治疗剂的经验表明，在大多数情况下，它们与不良CV结局相关，导致药物退市，并且人们对使用类似药物存在担忧。为了更好地了解用于减肥的药物治疗剂的CV风险和益处，本综述将讨论美国食品药品监督管理局（FDA）批准用于减肥的药物，以及通常用于该适应症的非标签药物。目标是概述这些药物中的许多药物可以提供的风险和益处，以帮助指导临床决策和患者教育。
